Biocon Ltd Q4FY21 consolidated PAT climbs to Rs. 253.2 crore

BIOCON LTD. has reported financial results for the period ended March 31, 2021.

Financial Results (Q4 FY20-21) - QoQ Comparison

The company has reported total income of Rs.2044.1 crores during the period ended March 31, 2021 as compared to Rs.1878.9 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.253.2 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.168.6 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.2.12 for the period ended March 31, 2021 as compared to Rs.1.40 for the period ended December 31, 2020.

Financials	Q4 FY20-21	Q3 FY20-21	% Change
Total Income	₹ 2044.1 crs	₹ 1878.9 crs	8.79%
Net Profit	₹ 253.2 crs	₹ 168.6 crs	50.18%
EPS	₹ 2.12	₹ 1.40	51.43%

Financial Results (Q4 FY20-21) - YoY Comparison

The company has reported total income of Rs.2044.1 crores during the period ended March 31, 2021 as compared to Rs.1620.6 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.253.2 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.123.4 crores for the period ended March 31, 2020.

The company has reported EPS of Rs.2.12 for the period ended March 31, 2021 as compared to Rs.1.04 for the period ended March 31, 2020.

Financials	Q4 FY20-21	Q4 FY19-20	% Change
Total Income	₹ 2044.1 crs	₹ 1620.6 crs	26.13%
Net Profit	₹ 253.2 crs	₹ 123.4 crs	105.19%
EPS	₹ 2.12	₹ 1.04	103.85%

Financial Results (Year ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.7360.3 crores during the 12 months period ended March 31, 2021 as compared to Rs.6461.9 crores during the 12 months period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.740.5 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.748.2 crores for the 12 months period ended March 31, 2020.

The company has reported EPS of Rs.6.19 for the 12 months period ended March 31, 2021 as compared to Rs.6.30 for the 12 months period ended March 31, 2020.

Financials	Year Ended FY20-21	Year Ended FY19-20	% Change
Total Income	₹ 7360.3 crs	₹ 6461.9 crs	13.9%
Net Profit	₹ 740.5 crs	₹ 748.2 crs	-1.03%
EPS	₹ 6.19	₹6.30	-1.75%

Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon,said: "In Q4FY21 our revenues grew 26% YoY to Rs 2,044 Crore driven by our Biosimilars, Research Services and Generics businesses. On a full-year basis, we reported a revenue growth of 14% led by Biosimilars which grew by 21%, Research Services by 9% and Generics by 6%. For FY21, EBITDA was at Rs 1,907 Crore and core EBITDA margins at 33%. Our determination to keep investing in science to stay a step ahead of the pandemic is reflected in the 19% rise in our Gross R&D spends in the year."

"As a science-led company we are contributing to the national fight against the pandemic, through several initiatives spanning diagnostic tests, vaccination and therapies towards combating COVID-19. The Biocon Group is catering to the countrywide demand for Remdesivir, Itolizumab and CytoSorb®. Syngene through its vaccination Centre is offering immunization services for Biocon Group employees as well to others operating in Electronic City, Bengaluru. Despite the challenges posed by the second COVID-19 wave in India, we will endeavor to have safe and uninterrupted operations and enable access to life-saving medicines for our patients and customers," she added.

Shares of BIOCON LTD. was last trading in BSE at Rs.390.95 as compared to the previous close of Rs. 398.2. The total number of shares traded during the day was 480935 in over 9687 trades.

The stock hit an intraday high of Rs. 399.8 and intraday low of 387.6. The net turnover during the day was Rs. 188187174.

Source : Equity Bulls

Keywords